Fortrea Holdings Inc. (FTRE)
| Market Cap | 2.14B +143.1% |
| Revenue (ttm) | 2.68B -2.1% |
| Net Income | -85.20M |
| EPS | -0.92 |
| Shares Out | 95.10M |
| PE Ratio | n/a |
| Forward PE | 23.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,837,670 |
| Open | 23.04 |
| Previous Close | 22.75 |
| Day's Range | 21.86 - 23.14 |
| 52-Week Range | 8.55 - 23.51 |
| Beta | 1.91 |
| Analysts | Buy |
| Price Target | 21.46 (-4.58%) |
| Earnings Date | Oct 29, 2026 |
About FTRE
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, ... [Read more]
Financial Performance
In 2025, Fortrea Holdings's revenue was $2.72 billion, an increase of 1.00% compared to the previous year's $2.70 billion. Losses were -$986.20 million, 200.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for FTRE stock is "Buy." The 12-month stock price target is $21.46, which is a decrease of -4.58% from the latest price.
News
Deutsche upgrades Fortrea to Buy on ‘fundamental inflection point’
Deutsche Bank upgraded Fortrea (FTRE) to Buy from Hold with a price target of $25, up from $20. The company is at a “fundamental inflection point” with better prospects for…
Fortrea upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Fortrea (FTRE) to Buy from Hold with a $25 price target
Fortrea price target raised to $15.50 from $13 at BofA
BofA analyst Avantika Dhabaria raised the firm’s price target on Fortrea (FTRE) to $15.50 from $13 and keeps an Underperform rating on the shares. The life science tools sector has…
Fortrea upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Fortrea (FTRE) to Overweight from Equal Weight with a price target of $23, up from $22. The firm believes Fortrea is the only contract research organization with margin…
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter ...
Fortrea initiated with a Neutral at UBS
UBS analyst Kevin Caliendo initiated coverage of Fortrea (FTRE) with a Neutral rating and $22 price target The firm sees low visibility into the company’s revenue inflection. Fortrea could fall…
Fortrea Holdings Transcript: 2026 Global Healthcare Conference
Leadership is driving growth through strategic acquisitions, expanding clinical pharmacology capacity, and prioritizing higher-margin business. Margins are targeted to reach mid-teens in 3-5 years, with operational leverage expected as service revenue grows. AI initiatives are underway, with industry-wide impact anticipated in 1-2 years.
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of...
Fortrea to Participate in September Investor Conferences
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP ...
Fortrea to buy Worldwide Clinical Trials Early Phase Services division for $45M
Fortrea (FTRE) and Worldwide Clinical Trials announced that they have signed a definitive agreement under which Fortrea will acquire Worldwide’s Early Phase Services division, consisting of its Clinic...
Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials
Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership...
Fortrea price target raised to $23 from $19 at TD Cowen
TD Cowen raised the firm’s price target on Fortrea (FTRE) to $23 from $19 and keeps a Buy rating on the shares. The firm remains confident in the company’s commercial…
Fortrea price target raised to $22 from $20 at Citi
Citi raised the firm’s price target on Fortrea (FTRE) to $22 from $20 and keeps a Buy rating on the shares.
Fortrea price target raised to $20 from $18 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Fortrea (FTRE) to $20 from $18 and keeps a Hold rating on the shares.
Fortrea price target raised to $23 from $21 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Fortrea (FTRE) to $23 from $21 and keeps an Outperform rating on the shares. The firm updated its model following…
Fortrea price target raised to $22 from $18 at Barclays
Barclays raised the firm’s price target on Fortrea (FTRE) to $22 from $18 and keeps an Equal Weight rating on the shares. The company reported a ‘strong beat across the…
Fortrea price target raised to $25 from $20 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on Fortrea (FTRE) to $25 from $20 and keeps an Outperform rating on the shares. Fortrea’s turnaround continues to track,…
Fortrea Holdings Earnings Call Transcript: Q2 2026
Second quarter results exceeded expectations, with improved full-year guidance and strong commercial momentum, especially in biotech. Revenue declined year-over-year due to lower passthroughs, but adjusted EBITDA and cash flow improved, supported by cost savings and operational efficiencies.
Fortrea Holdings Slides: Q2 2026
Fortrea Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Fortrea Holdings Earnings release: Q2 2026
Fortrea Holdings released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Fortrea Holdings Quarterly report: Q2 2026
Fortrea Holdings has published its Q2 2026 quarterly earnings report on July 29, 2026.
Fortrea reports Q2 adjusted EPS 23c, consensus 18c
Reports Q2 revenue $678.2M, consensus $647.59M. “Our Q2 results reflect continued progress against our strategy and disciplined execution across the business,” said Anshul Thakral, CEO of Fortrea (FTR...
Fortrea Reports Second Quarter 2026 Results
Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance
Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2...
Fortrea price target raised to $16 from $13 at Mizuho
Mizuho raised the firm’s price target on Fortrea (FTRE) to $16 from $13 and keeps a Neutral rating on the shares. The firm adjusted targets in the healthcare facilities and…